A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

Conditions: Ovarian Neoplasms; Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma
Interventions: Drug: Niraparib; Drug: Dostarlimab (TSR-042); Drug: Standard of care; Drug: Dostarlimab-Placebo; Drug: Niraparib-Placebo
Sponsors: Tesaro, Inc.; European Network of Gynaecological Oncological Trial Groups (ENGOT)
Active, not **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

June 5, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments